Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism.

Winer KK, Sinaii N, Peterson D, Sainz B Jr, Cutler GB Jr

The Journal of clinical endocrinology and metabolism20 May 2008Cited by 98 (Europe PMC)

PMID18492754PMCIDPMC2567852DOI10.1210/jc.2007-2552PepBankPUB-18492754

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In children with hypoparathyroidism, PTH maintained mean predose serum calcium just below normal.
In plain wordsIn children with hypoparathyroidism, PTH maintained predose blood calcium just below normal.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicablePredose serum calcium
Study
n = 14
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
Dose not stated · 14 weeksAs given in this study (human).
Source sentences
Summary
Mean predose serum calcium was maintained at levels just below the normal range.
1 context sentence(design, population, supporting numbers)
Summary · context
Fourteen children ages 4-17 yr with chronic hypoparathyroidism were studied.Study designThis was a randomized cross-over trial, lasting 28 wk, which compared two dose regimens, once-daily vs. twice-daily PTH1-34. Each 14-wk study arm was divided into a 2-wk inpatient dose-adjustment phase a…
Report a problemFND-1849275401
02HumanRandomized controlled trialEfficacy outcome
In children with hypoparathyroidism, twice-daily PTH increased serum calcium more effectively than once-daily PTH.
In plain wordsIn children with hypoparathyroidism, twice-daily PTH increased blood calcium more effectively than once-daily PTH.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum calcium
Study
n = 14
Comparator
Once-daily PTH
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
Dose not stated · 14 weeksAs given in this study (human).
Source sentences
Summary
Repeated serum measures over a 24-h period showed that twice-daily PTH 1-34 increased serum calcium and magnesium levels more effectively than a once-daily dose. This was especially evident during the second half of the day (12-24 h).
1 context sentence(design, population, supporting numbers)
Summary · context
Fourteen children ages 4-17 yr with chronic hypoparathyroidism were studied.Study designThis was a randomized cross-over trial, lasting 28 wk, which compared two dose regimens, once-daily vs. twice-daily PTH1-34. Each 14-wk study arm was divided into a 2-wk inpatient dose-adjustment phase a…
Report a problemFND-1849275402
03HumanRandomized controlled trialEfficacy outcome
In children with hypoparathyroidism, twice-daily PTH increased serum magnesium more effectively than once-daily PTH.
In plain wordsIn children with hypoparathyroidism, twice-daily PTH increased blood magnesium more effectively than once-daily PTH.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum magnesium
Study
n = 14
Comparator
Once-daily PTH
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
Dose not stated · 14 weeksAs given in this study (human).
Source sentences
Summary
Repeated serum measures over a 24-h period showed that twice-daily PTH 1-34 increased serum calcium and magnesium levels more effectively than a once-daily dose. This was especially evident during the second half of the day (12-24 h).
1 context sentence(design, population, supporting numbers)
Summary · context
Fourteen children ages 4-17 yr with chronic hypoparathyroidism were studied.Study designThis was a randomized cross-over trial, lasting 28 wk, which compared two dose regimens, once-daily vs. twice-daily PTH1-34. Each 14-wk study arm was divided into a 2-wk inpatient dose-adjustment phase a…
Report a problemFND-1849275403
04HumanRandomized controlled trialEfficacy outcome
In children with hypoparathyroidism, both PTH schedules normalized mean daily urine calcium excretion.
In plain wordsIn children with hypoparathyroidism, both PTH schedules normalized daily urine calcium loss.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableUrine calcium excretion
Study
n = 14
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
Dose not stated · 14 weeksAs given in this study (human).
Source sentences
Summary
PTH 1-34 normalized mean 24-h urine calcium excretion on both treatment schedules.
1 context sentence(design, population, supporting numbers)
Summary · context
Fourteen children ages 4-17 yr with chronic hypoparathyroidism were studied.Study designThis was a randomized cross-over trial, lasting 28 wk, which compared two dose regimens, once-daily vs. twice-daily PTH1-34. Each 14-wk study arm was divided into a 2-wk inpatient dose-adjustment phase a…
Report a problemFND-1849275404
05HumanRandomized controlled trialEfficacy outcome
In children with hypoparathyroidism, twice-daily PTH achieved control with a lower daily dose than once-daily PTH.
In plain wordsIn children with hypoparathyroidism, twice-daily PTH achieved control with less daily PTH than once-daily treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseDaily PTH requirement
Study
n = 14
Comparator
Once-daily PTH
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
Dose not stated · 14 weeksAs given in this study (human).
Measurements
Daily dose
25 microg/d
twice-daily
Daily dose
58 microg/d
once-daily
Source sentences
Summary
This was achieved with half the PTH 1-34 dose during the twice-daily regimen compared with the once-daily regimen (twice-daily, 25 +/-15 microg/d vs. once-daily, 58 +/- 28 microg/d; P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Fourteen children ages 4-17 yr with chronic hypoparathyroidism were studied.Study designThis was a randomized cross-over trial, lasting 28 wk, which compared two dose regimens, once-daily vs. twice-daily PTH1-34. Each 14-wk study arm was divided into a 2-wk inpatient dose-adjustment phase a…
Report a problemFND-1849275405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00001304

Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)n = 27Oct 1991 to Apr 2014

Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 15 Dec 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.